GoldenGolden
Advanced Search
PTC Therapeutics

PTC Therapeutics

A biopharmaceutical company focused on discovery and development of small-molecule drugs to treat genetic and rare diseases

PTC Therapeutics is a publicly owned biopharmaceutical company that is headquartered in South Plainfield, New Jersey and was founded in 1998 by Stuart W. Peltz and Allan Jacobson.

The company focuses on the discovery, development, and commercialization of treatments for orphan and rare disorders. The company is in the particular are of developing orally-administered, proprietary small molecule drugs that target post transcriptional control processes. These are processes that regulate the rate and timing of protein production and are essential to proper cellular function.

Products

PTC has launched two rare disorder products, Translarna (ataluren) and Emflaza (deflazacort).

Translarna

Translarna is a treatment for Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene. It has been approved for ambulatory patients aged 2 years and above in the European Union. In the US, it holds the status of an investigational new drug.

Emflaza

Emflaza is another treatment for Duchenne muscular dystrophy in patients aged 5 years and above. It is approved in the US. PTV has also gained the commercialization rights for Tegsedi (inotersen), a treatment for polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) in adults, in Latin America.

Acquisitions
Agilis Biotherapeutics

In August 2018, PTC announced its acquisition of Agilis Biotherapeutics, a private biotechnology company focused on the development of gene therapy programs for rare genetic disorders that affect the central nervous system. Through this acquisition, PTC added GT-AADC, an adeno-associated virus (AAV) gene therapy that treats Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency.

It also added several other gene therapy programs in development, including, GT-FA, GT-AS, and GT-RLN, for Freidreich Ataxia, Angelman Syndrome, and Cognitive Disorders assiciated with severe neurodevelopmental and neurodegenerative disorders, respectively.

Timeline

November 17, 2020
PTC Therapeutics announces that PTC518 has entered into a Phase 1 Clinical Trial for the Huntington's Disease Program.

June 10, 2020
PTC Therapeutics Launches New "Talent Pipeline Program" to Help Students who Graduated During the 2020 COVID-19 Pandemic.

June 1, 2020
PTC Therapeutics acquires Censa Pharmaceuticals.
December 22, 2009
PTC Therapeutics raises a $50,000,000 series E round from Credit Suisse, Delphi Ventures, HBM BioVentures and The Column.
1998
PTC Therapeutics was founded by Allan Jacobson.

Funding rounds

People

Name
Role
LinkedIn

Annie Zhao

Employee

Christine Utter

Principal Financial Officer and Treasurer

Clarissa Diniz

Employee

Jeffrey Wickham

Employee

Marcio Souza

COO

Mark E. Boulding

Executive VP & Chief Legal Officer

Mark J. Pykett

Chief Innovation Officer

Martin Rexroad

Senior VP, Human Resources

Mary Frances Harmon

Senior VP, Corporate Relations

Megan Sniecinski

Senior VP, Business Operations and Program Management

Neil Almstead

Executive VP - Research, Pharmaceutical Operations & Technology

Quintus Ngumah

Employee

Roni H. Amiel

Employee

Stanley Lue

Employee

Steve Hall

Investor

Stuart W. Peltz

CEO

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
PTC Therapeutics
June 18, 2021
www.prnewswire.com:443
/PRNewswire/ -- A PTC Therapeutics, uma empresa biofarmacêutica global voltada para a ciência, anunciou recentemente dados do primeiro estudo sobre o impacto...
PTC Therapeutics, Inc.
June 15, 2021
www.prnewswire.com:443
/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 11, 2021 it approved non-statutory stock options to purchase an aggregate of...
PTC Therapeutics, Inc.
June 11, 2021
www.prnewswire.com:443
/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced positive interim results from the ongoing RAINBOWFISH trial that demonstrated...
PTC Therapeutics, Inc.
May 4, 2021
www.prnewswire.com:443
/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and financial results for the first quarter ending March 31, 2021....
PTC Therapeutics, Inc.
April 19, 2021
www.prnewswire.com:443
/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 13, 2021 it approved non-statutory stock options to purchase an aggregate...
PTC Therapeutics, Inc.
April 15, 2021
www.prnewswire.com:443
/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that results from Part 2 of the pivotal FIREFISH trial demonstrated that infants with...
April 14, 2021
BioSpace
PTC Therapeutics Launches the PTC Pinpoint DirectTM Program for Patient-Initiated Genetic Testing - read this article along with other careers information, tips and advice on BioSpace
BioSpace
April 7, 2021
BioSpace
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has been named a winner of the 2021 "Don Clifton Strengths-Based Culture Award" from Gallup.
PTC Therapeutics, Inc.
February 26, 2021
www.prnewswire.com:443
/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use...
PTC Therapeutics, Inc.
February 24, 2021
www.prnewswire.com:443
/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced the publication of results from the dose finding Part 1 of the pivotal FIREFISH study...
PTC Therapeutics, Inc.
February 4, 2021
www.prnewswire.com:443
/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a conference call today at 5:30 p.m. E.T. to review results from its clinical study 045 of...
PTC Therapeutics
January 28, 2021
www.prnewswire.com:443
/PRNewswire/ -- A PTC Therapeutics, empresa biofarmacêutica global focada na descoberta, no desenvolvimento e na comercialização de terapias para doenças...
PTC Therapeutics
January 28, 2021
www.prnewswire.com:443
/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) anunció el lanzamiento del séptimo programa anual de Premios STRIVE para distrofia muscular de Duchenne...
PTC Therapeutics, Inc.
January 13, 2021
www.prnewswire.com:443
/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on January 6, 2021 it approved non-statutory stock options to purchase an aggregate...
PTC Therapeutics, Inc.
January 11, 2021
www.prnewswire.com:443
/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will present an update on its R&D pipeline and commercial progress at the 39th Annual J.P. Morgan...
PTC Therapeutics, Inc.
December 18, 2020
www.prnewswire.com:443
/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on December 15, 2020 it approved non-statutory stock options to purchase an...
PTC Therapeutics, Inc.
December 4, 2020
www.prnewswire.com:443
/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on December 2, 2020 it approved non-statutory stock options to purchase an aggregate...
PTC Therapeutics, Inc.
December 4, 2020
www.prnewswire.com:443
/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that TranslarnaTM (ataluren) has been granted marketing approval in the Russian Federation...
BioSpace
November 25, 2020
BioSpace
Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, announced today that it has expanded its partnership with PTC Therapeutics, Inc
Mark Terry
November 23, 2020
BioSpace
Although there was quite a bit of clinical trial news overall, the biggest focus was on COVID-19 vaccines, with the three leaders in the U.S. and Europe all presenting clinical trial news. Here's a look.
SHOW MORE

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.